Skip to content

MOLN

Molecular Partners AG

NASDAQ · Healthcare · Biotechnology · CH

$3.66
+2.81%
Ask drillr

Forward multiples

Based on analyst estimates

P/E forward
—
P/E 2026E
—
P/E 2027E
—
P/E 2028E
—
P/S forward
—

Trailing multiples

Trailing twelve months

P/E TTM
—
PEG TTM
—
Price / book
1.98x
Price / sales
—
Price / cash flow
-2.24x

Enterprise value

Enterprise value
$61.7M
EV / sales
—
EV / EBITDA
-0.92x
EV / EBIT
-0.88x
Market cap
$140.2M

Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026